Altered behavioural and neurochemical profile of l-DOPA following deuterium substitutions in the molecule

Experimental Neurology

Volumn 212, Issue 2, 2008, Pages 538-542

  Malmlöf, Torun ^a   Svensson, Torgny H ^a   Schilström, Björn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Brain; Carbidopa; Catecholamine; Dyskinesia; Enzyme; Isotope; Metabolism; Precursor; Rat; Reserpine

Indexed keywords

ANTIPARKINSON AGENT; BETA BETA D2 LEVODOPA; CARBIDOPA; CARBON; D3 LEVODOPA; DEUTERIUM; DOPAMINE; LEVODOPA; RESERPINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG EFFECT; LOCOMOTION; MALE; MICRODIALYSIS; MOLECULE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CARBIDOPA; DEUTERIUM; DOPAMINE; DOPAMINE AGENTS; LEVODOPA; MALE; MICRODIALYSIS; MOTOR ACTIVITY; RATS; RATS, WISTAR; TIME FACTORS;

EID: 47549115977     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.05.003     Document Type: Article

References (16)

1. Calabresi P., Giacomini P., Centonze D., and Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. Ann. Neurol. 47 Suppl 1 (2000) S60-69
2. Foster A.B. Deuterium isotope effects in the metabolism of drugs and xenobiotics: implication for drug design. Adv. Drug Res. 14 (1985) 1-40
3. Kushner D.J., Baker A., and Dunstall T.G. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can. J. Physiol. Pharmacol. 77 (1999) 79-88
4. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977) 345-349
5. Miller S.M., and Klinman J.P. Magnitude of intrinsic isotope effects in the dopamine b-monooxygenase reaction. Biochemistry 22 (1983) 3091-3096
6. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40 (1990) 340-345
7. Nutt J.G., Woodward W.R., Beckner R.M., Stone C.K., Berggren K., et al. Effect of peripheral catechol-O-methyltransferase inhibition of the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44 (1994) 913-919
8. Olanow C.W., and Obeso J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 55 Suppl 1 (2000) 56-63
9. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5 (2006) 677-687
10. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed (1998), Academic Press, New York
11. Rajput A.H., Fenton M.E., Birdi S., Macaulay R., George D., et al. Clinical-pathological study of levodopa complications. Mov. Disord. 17 (2002) 289-296
12. Rascol O., Arnulf I., Peyro Saint Paul H., Brefel-Courbon C., Vidailhet M., et al. Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 16 (2001) 708-713
13. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 55 Suppl 1 (1998) 23-30
14. Smith L.A., Jackson M.J., Al-Barghouthy G., Rose S., Kuoppamaki M., et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. 20 (2005) 306-314
15. Yu P.H., Kazakoff C., Davis B.A., and Boulton A.A. Deuterium isotope effect on enzymatic oxidation of dopamine and serotonin. Biochem. Pharmacol. 31 (1982) 3697-3698
16. Yu P.H., Bailey B.A., Durden D.A., and Boulton A.A. Stereospecific deuterium substitution at the α-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues. Biochem. Pharmacol. 35 (1986) 1027-1036